CLIFF (Cordlife Group) Dividends Received

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CLIFF Cordlife Group Ltd CLIFF
42 GF Score
Price $0.15
GF Value $0.08
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Cordlife Group Dividends Received?

Dividends Received only applicable to companies reporting Cash Flow from Operations in direct method.

CLIFF
42GF Score
Cordlife Group Ltd CLIFF
Dividends Received is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Cordlife Group (CLIFF) Overvalued in 2026?

Based on GuruFocus' analysis, Cordlife Group stock appears to be overvalued. The current stock price of $0.15 is trading 88.1% above its estimated GF Value™ of $0.08. GuruFocus considers Cordlife Group to be Significantly Overvalued.

Key valuation signals for CLIFF:

  • Dividends Received:
  • GF Value™: $0.08 vs. price of $0.15 (88.1% above fair value)
  • GF Score™: 42/100 with 4 warning signs

No single metric tells the full story. See the CLIFF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Cordlife Group Business Description

Other Exchanges P8A:Singapore
Address 1 Kim Seng Promenade, No. 15-01, Great World City East, Singapore, SGP, 237994
Cordlife Group Ltd is a consumer healthcare company dedicated to safeguarding the well-being of mother and child. Along with its subsidiaries, the company is engaged in the provision of diagnostics and cord blood banking services, which involve the processing and storage of cord blood stem cells. The group has two reportable segments as follows: the Banking segment, which derives maximum revenue, comprises the collection, processing, and banking of biological materials; and the Diagnostics segment, which comprises diagnostics testing services. Geographically, the group generates maximum revenue from Hong Kong, and the rest from the Philippines, India, Malaysia, Singapore, and other regions.
42GF Score

Get the complete analysis for CLIFF

Dividends Received is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.15
Price
$0.08
GF Value